Vascular calcification and disordered mineral metabolism in dialysis patients
- PMID: 17374088
- DOI: 10.1111/j.1525-139X.2007.00261.x
Vascular calcification and disordered mineral metabolism in dialysis patients
Abstract
Vascular calcification is an active, cell-mediated process that can involve either the intima or media of the blood vessels. The current methods used to clinically measure vascular calcification cannot distinguish between intimal (invariably atherosclerotic) and medial calcification. The high calcification scores seen in patients with end-stage renal disease likely represent a composite of high calcification burden in both sites. The severity of vascular calcification has been associated with a variety of findings including left ventricular hypertrophy and angiographic vascular stenosis as well as with all-cause and cardiovascular mortality. There is increasing evidence that disordered mineral metabolism participates in the process of vascular calcification and is one of the mechanisms whereby hyperphosphatemia, hypercalcemia, and hyperparathyroidism enhance cardiovascular and all-cause mortality of end-stage renal disease patients. There are no studies showing improved outcomes of ESRD patients with aggressive control of disordered mineral metabolism. However, the preponderance of evidence argues strongly in favor of aggressive management of these abnormalities from starting early in the course of chronic kidney disease in the hope of improving patient outcomes.
Similar articles
-
Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.J Ren Nutr. 2006 Apr;16(2):100-18. doi: 10.1053/j.jrn.2006.01.006. J Ren Nutr. 2006. PMID: 16567266 Review.
-
Vascular calcification and ESRD: a hard target.Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S102-5. doi: 10.2215/CJN.04800709. Clin J Am Soc Nephrol. 2009. PMID: 19995990 Review.
-
[Pathogenesis and therapy for vascular calcification in patients on chronic hemodialysis].Clin Calcium. 2005 Jul;15(7):106-14. Clin Calcium. 2005. PMID: 15995305 Review. Japanese.
-
[Experimental study of the mechanism for vascular calcification in chronic kidney disease].Verh K Acad Geneeskd Belg. 2008;70(4):285-303. Verh K Acad Geneeskd Belg. 2008. PMID: 19166100 Review. Dutch.
-
[Vascular calcification: types and mechanisms].Nefrologia. 2011;31(2):142-7. doi: 10.3265/Nefrologia.pre2010.Nov.10754. Nefrologia. 2011. PMID: 21461006 Review. Spanish.
Cited by
-
Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.Drugs. 2007;67(14):1981-98. doi: 10.2165/00003495-200767140-00002. Drugs. 2007. PMID: 17883283 Review.
-
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.Clin J Am Soc Nephrol. 2008 Sep;3(5):1437-45. doi: 10.2215/CJN.04741107. Epub 2008 Jun 25. Clin J Am Soc Nephrol. 2008. PMID: 18579668 Free PMC article. Clinical Trial.
-
Serum osteoprotegerin level in hemodialysis patients using low-flux reused dialyzer in relation to atherosclerosis.J Clin Lab Anal. 2021 Aug;35(8):e23886. doi: 10.1002/jcla.23886. Epub 2021 Jun 26. J Clin Lab Anal. 2021. PMID: 34173983 Free PMC article.
-
No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.Kidney Int. 2013 Nov;84(5):989-97. doi: 10.1038/ki.2013.145. Epub 2013 Apr 24. Kidney Int. 2013. PMID: 23615501 Free PMC article.
-
Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.Clin J Am Soc Nephrol. 2008 Jan;3(1):61-8. doi: 10.2215/CJN.02810707. Epub 2007 Dec 5. Clin J Am Soc Nephrol. 2008. PMID: 18057307 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical